| __timestamp | MiMedx Group, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 12665000 | 125883000 |
| Thursday, January 1, 2015 | 20202000 | 69036000 |
| Friday, January 1, 2016 | 32407000 | 72700000 |
| Sunday, January 1, 2017 | 35219000 | 105700000 |
| Monday, January 1, 2018 | 36386000 | 198700000 |
| Tuesday, January 1, 2019 | 43081000 | 117600000 |
| Wednesday, January 1, 2020 | 39330000 | 108100000 |
| Friday, January 1, 2021 | 43283000 | 122500000 |
| Saturday, January 1, 2022 | 48316000 | 146700000 |
| Sunday, January 1, 2023 | 54634000 | 257500000 |
Infusing magic into the data realm
In the ever-evolving landscape of the pharmaceutical industry, understanding cost structures is crucial. Over the past decade, United Therapeutics Corporation and MiMedx Group, Inc. have shown distinct trends in their cost of revenue. From 2014 to 2023, United Therapeutics consistently maintained a higher cost of revenue, peaking at $258 million in 2023, a 105% increase from 2015. In contrast, MiMedx Group's cost of revenue grew steadily, reaching $55 million in 2023, marking a 170% rise since 2014. This divergence highlights United Therapeutics' larger scale of operations, while MiMedx's growth trajectory underscores its expanding market presence. These insights provide a window into the strategic financial maneuvers of these companies, reflecting broader industry trends and competitive dynamics.
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: United Therapeutics Corporation vs PTC Therapeutics, Inc.
Cost of Revenue Trends: United Therapeutics Corporation vs HUTCHMED (China) Limited
Gross Profit Trends Compared: United Therapeutics Corporation vs MiMedx Group, Inc.
Viatris Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Analyzing Cost of Revenue: Pharming Group N.V. and MiMedx Group, Inc.
Cost of Revenue Comparison: Cytokinetics, Incorporated vs MiMedx Group, Inc.